Nucana presents encouraging data on nuc-7738 in combination with pembrolizumab in pd-1 inhibitor refractory and resistant melanoma patients at the esmo congress 2024

Combination of nuc-7738 plus pembrolizumab resulted in prolonged progression free survival, a compelling disease control rate including partial responses, and a favorable safety profile combination of nuc-7738 plus pembrolizumab resulted in prolonged progression free survival, a compelling disease control rate including partial responses, and a favorable safety profile
NCNA Ratings Summary
NCNA Quant Ranking